GHRP-6
← Back to LibraryCompound Profile
GHRP-6 is reviewed here for growth-hormone signaling and recovery context.
Research Summary
Safety notices, literature searches, limited protocol data
Growth-hormone signaling, Recovery, Body composition
Target context: GHS-R1a
Limited, unclear, or affected by safety flags.
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
100 mcg
Dosing window
Pre-Meal
Receptor / target
GHS-R1a
Properties
GH Secretagogue
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
| Weeks 3-4 | 200 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
| Weeks 5-12 | 300 mcg 3x Daily | AM Upon Waking, Mid-Day, PM Before Bedtime. Administered 30 mins before meals to maximize appetite increase. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative 1: Performance / Muscle Growth
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 250mcg 3x Daily | AM upon waking, Post-workout, PM before bedtime. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative 2: Anti-Aging Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg 2x Daily | AM upon waking, PM before bedtime. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied around pituitary GH signaling, IGF-1 response, body-composition endpoints, growth-hormone deficiency models, or discontinued anabolic programs depending on the compound. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: GHS-R1a. Route(s): Subcutaneous. Dosing window on page: Pre-Meal. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- GH-axis compounds are best interpreted through pituitary physiology, IGF-1 response, pulse timing, and metabolic adverse effects rather than dose escalation alone.
- Evidence strength ranges from approved labels for specific agents to sparse or discontinued development programs for research peptides.
- FDA lists GHRP-6 in category 2 with immunogenicity/impurity concerns and limited safety information.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-2, 100 mcg 3x Daily; Alternative 1: Performance / Muscle Growth: Weeks 1-12, 250mcg 3x Daily.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor IGF-1 response, fasting glucose/A1c, edema, carpal-tunnel symptoms, blood pressure, sleep apnea, and malignancy history.
Selected medical sources
Independent evidence
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active malignancy: GH/IGF-1 elevation may accelerate tumor growth.
- History of pituitary tumor or pituitary adenoma.
- Individuals struggling with weight management, obesity, or binge eating disorders: extreme ghrelin-mediated hunger will make caloric control nearly impossible.
- Eating disorders (anorexia nervosa, bulimia, binge eating disorder): extreme hunger stimulation is dangerous in these populations.
- Uncontrolled diabetes mellitus or severe insulin resistance: GH elevation worsens glucose metabolism.
- Diabetic ketoacidosis.
- History of prolactinoma or elevated prolactin: GHRP-6 significantly elevates prolactin.
- High baseline cortisol or adrenal insufficiency: additive HPA axis stimulation from cortisol-elevating mechanism.
- Anxiety disorders or high-stress baseline: cortisol elevation amplifies anxiety response.
- Concurrent use with ipamorelin or GHRP-2: receptor competition; do not stack two GHRPs.
- Concurrent use with HGH 191aa: redundant GH axis overstimulation.
- Concomitant high-dose glucocorticoids: attenuates GH response and amplifies cumulative cortisol load.
- Concomitant GLP-1 receptor agonists where appetite conflict is clinically significant: the extreme hunger from GHRP-6 directly counteracts GLP-1 appetite suppression.
- Pregnancy: safety not established.
- Breastfeeding: safety not established.
- Known hypersensitivity to GHRP-6 or excipients.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Extreme, uncontrollable hunger: the defining and most clinically significant adverse effect; onset within 15-20 minutes of injection; the most intense appetite stimulation of any compound in this database; described as urgent, compulsive, ghrelin-mediated hunger drive.
- Significant cortisol elevation: most pronounced cortisol increase among the GHRPs; transient per injection but cumulative with multi-daily dosing.
- Significant prolactin elevation: elevated via GHS-R1a activation on pituitary lactotrophs; chronic elevation increases gynecomastia risk in men and may cause menstrual irregularities.
- ACTH elevation: adrenocorticotrophic hormone released alongside cortisol via HPA axis activation.
- Water retention and peripheral edema: GH-mediated sodium and fluid retention; pronounced at 3x daily protocols.
- Head rush and transient flushing: acute GH pulse-induced vasodilation.
- Joint stiffness and arthralgia.
- Tingling or numbness in extremities.
- Vivid dreams: GH elevation during nocturnal sleep.
- Lethargy post-injection: associated with the GH pulse.
- Headache.
- Injection site irritation.
- Insulin resistance: GH elevation at 3x daily protocols; monitor fasting glucose.
- Potential for significant weight gain if caloric intake is not managed: extreme appetite stimulation can easily produce caloric surplus that exceeds the lean mass benefit.
- Receptor desensitization with extended cycles: less rapid than hexarelin but present; requires 2-4 week washout after 6-12 week cycles.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: